Clarithromycin is an antibiotic used to treat bacterial infections such as respiratory tract infections, ear infections, and skin infections. It works by stopping bacteria from growing and multiplying.[2] Biaxin is currently approved and in use across 56 indications[4].[1]
Biaxin is one of 967 small molecule programs targeting Bacterial Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
1931 competitors in COVID-19
Biaxin
Singulair
Activella
Benadryl
Rayaldee
Low-Molecular-Weight Heparin
Statin
Orap
Olokizumab
DAS181
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 31, 1991
BIAXIN
NDA NDA050662
Dec 23, 1993
BIAXIN
NDA NDA050698
Mar 3, 2000
BIAXIN XL
NDA NDA050775
Sources